BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180323
DTEND;VALUE=DATE:20180328
DTSTAMP:20260729T122632
CREATED:20170508T150834Z
LAST-MODIFIED:20171001T151229Z
UID:17907-1521763200-1522195199@ces.b2sg.org
SUMMARY:Chromatin Architecture and Chromosome Organization (X5) in Whistler\, Canada
DESCRIPTION:The meeting will begin on Friday\, March 23 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Tuesday\, March 27 with a closing plenary session from 17:00 to 19:00\, followed by a social hour and entertainment. We recommend return travel on Wednesday\, March 28 in order to fully experience the meeting.  \nSpeakers: \nKaren Adelman\, Harvard Medical School\, USA  \nGeneviève Almouzni\, Centre National de la Recherche Scientifique\, France  \nCheryl Arrowsmith\, University of Toronto\, Canada  \nEmily Bernstein\, Mount Sinai School of Medicine\, USA \nWendy A. Bickmore\, University of Edinburgh\, UK  \nJames E. Bradner\, Novartis Institutes for BioMedical Research\, USA  \nClifford P. Brangwynne\, Princeton University\, USA  \nGiacomo Cavalli\, Institute of Human Genetics\, France  \nIbrahim Cissé\, Massachusetts Institute of Technology\, USA \nVictor G. Corces\, Emory University\, USA  \nPatrick Cramer\, Max Planck Institute for Biophysical Chemistry\, Germany  \nJob Dekker\, University of Massachusetts Medical School\, USA  \nJennifer A. Doudna\, HHMI/University of California\, Berkeley\, USA  \nDenis Duboule\, EPFL-SV-ISREC-UPDUB\, Switzerland  \nJoseph R. Ecker\, The Salk Institute for Biological Studies\, USA  \nRonald M. Evan\, Howard Hughes Medical Institute\, Salk Institute\, USA \nPeter Fraser\, Florida State University\, USA  \nEileen E.M. Furlong\, European Molecular Biology Laboratory\, Germany  \nSusan M. Gasser\, Friedrich Miescher Institute for Biomedical Research\, Switzerland  \nWilliam J. Greenleaf\, Stanford University\, USA  \nMitchell Guttman\, California Institute of Technology\, USA \nSuzana Hadjur\, University College London\, UK \nEdith Heard\, Institut Curie\, France  \nManolis Kellis\, Massachusetts Institute of Technology / Broad Institute\, USA  \nWouter de Laat\, Hubrecht Institute\, Netherlands   \nMichael S. Levine\, Princeton University\, USA  \nRoss L. Levine\, Memorial Sloan Kettering Cancer Center\, USA \nStavros Lomvardas\, Columbia University\, USA  \nMarc A. Marti-Renom\, CNAG-CRG\, Spain  \nLeonid Mirny\, Massachusetts Institute of Technology\, USA  \nStefan Mundlos\, Max Planck Institute for Molecular Genetics\, Germany \nGeeta J. Narlikar\, University of California\, San Francisco\, USA   \nWilliam Stafford Noble\, University of Washington\, USA \nAna Pombo\, Max-Delbrück-Centrum für Molekulare Medizin\, Germany  \nOliver J. Rando\, University of Massachusetts Medical School\, USA  \nKaren L. Reddy\, Johns Hopkins University\, USA  \nBing Ren\, Ludwig Institute for Cancer Research\, USA  \nPeter C. Scacheri\, Case Western Reserve University\, USA  \nPhillip A. Sharp\, Massachusetts Institute of Technology\, USA \nJane A. Skok\, New York University School of Medicine\, USA  \nMikhail Spivakov\, Babraham Institute\, UK  \nJohn A. Stamatoyannopoulos\, University of Washington\, USA  \nBas van Steensel\, Netherlands Cancer Institute\, Netherlands \nAmos Tanay\, Weizmann Institute\, Israel  \nJuanma Vaquerizas\, Max Planck Institute for Molecular Biomedicine\, Germany \nJoanna Wysocka\, Stanford University School of Medicine\, USA  \nRichard A. Young\, Whitehead Institute for Biomedical Research\, USA  \nMagdalena Zernicka-Goetz\, University of Cambridge\, UK  \nLeonard I. Zon\, HHMI/Boston Children’s Hospital\, USA  \n  \nScholarship Deadline: Nov 28\, 2017\n Discounted Abstract Deadline: Nov 28\, 2017\n Abstract Deadline: Dec 20\, 2017\n Discounted Registration Deadline: Jan 17\, 2018 \n  \n 
URL:https://ces.b2sg.org/event/keystone-mar2018/
LOCATION:Whistler Conference Centre\, 4010 Whistler Way\, Whistler\, V0N 1B4\, Canada
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/keystone-e1494159273833.jpg
END:VEVENT
END:VCALENDAR